等待開盤 06-13 09:30:00 美东时间
-0.280
-4.36%
今日重点评级关注:Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从6美元升至10美元;Ascendiant Capital:维持Aytu BioPharma"买入"评级,目标价从14美元升至14.5美元
06-12 11:32
Northland Capital Markets analyst Robert Brooks initiates coverage on CitroTech Inc. Common Stock (AMEX:CITR) with a Outperform rating and announces Price Target of $16.
06-11 21:26
CitroTech (NYSE AM: CITR) today announced the continued expansion of its intellectual property (IP) portfolio, reinforcing its position as the only company in wildfire prevention whose platform combines GPS-enabled
06-04 20:40
CitroTech files Form 3 initial beneficial ownership statement for director Lorenzo Calinawan CitroTech filed a Form 3 naming Lorenzo Calinawan as a director, dated Oct. 15, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUB
06-02 08:25
The latest update is out from General Enterprise Ventures ( ($CITR) ). On May 2...
06-02 06:08
Gainers Kornit Digital (NASDAQ:KRNT) stock rose 18.3% to $17.0 during Thursday...
05-21 20:06
CitroTech Inc. (NYSE AM: CITR), a leading specialty chemical company delivering environmentally-safe fire inhibitor solutions, and Hexion Inc., a leading global producer of adhesives and performance materials and
04-21 20:08
General Enterprise Ventures ( ($CITR) ) has shared an update. On April 1, 2026,...
04-04 00:28
CitroTech announces availability of shareholder letter CitroTech announced availability of a letter to shareholders outlining accelerated growth plans following its December uplist to NYSE American in fiscal 2025. Revenue rose to USD 2.4 million in 2025 from USD 808,000 in 2024, reflecting broader a
03-30 21:01
CitroTech FY25 net loss widens 435% to $37 million; revenue more than tripled to $2.4 million CitroTech posted a net loss of $37 million, widening 435%. Revenue more than tripled to $2.4 million, up 195%. Operating expenses jumped to $19 million, up 209%. Growth was driven by broader adoption of Cit
03-30 18:10